Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.46 |
| ▸ | ITGAL | P20701 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | PYGL | P06737 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780480 | 1.00 | HSP90AA1 (0.65) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Hydrochloric Acid SCHEMBL11122742 | 0.99 | HSP90AA1 (0.67) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Hydrochloric Acid SCHEMBL11122746 | 0.99 | HSP90AA1 (0.67) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Water SCHEMBL11120619 | 0.92 | HSP90AA1 (0.57) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Water SCHEMBL11120616 | 0.92 | HSP90AA1 (0.57) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Cadaverine Tartrate SCHEMBL11197504 | 0.92 | HSP90AA1 (0.60) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Cadaverine Tartrate SCHEMBL11119965 | 0.92 | HSP90AA1 (0.60) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Citric Acid SCHEMBL11120376 | 0.89 | HSP90AA1 (0.55) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| Citric Acid SCHEMBL11120383 | 0.89 | HSP90AA1 (0.55) | HSP90AA1NPC1RAB9ATDP1PAX8 | |
| SCHEMBL780339 | 0.86 | HSP90AA1 (0.74) | HSP90AA1NPC1RAB9AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0043141-B1 | PHARMACEUTICAL COMPOSITIONS HAVING ANTIVIRAL ACTIVITY FOR TOPICAL ADMINISTRATION AND THE USE OF 1-(SUBSTITUTED PHENYL)-5-(4-MORPHOLINYL)-1-PENTEN-3-ONE COMPOUNDS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING AN ANTIVIRAL EFFECT | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-09-12 | — | — | EP | claimed |
| US-4400380-A | HERBES VIRUS; TOPICAL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-08-23 | — | — | US | claimed |
| EP-0043141-A1 | Pharmaceutical compositions having antiviral activity for topical administration and the use of 1-(substituted phenyl)-5-(4-morpholinyl)-1-penten-3-one compounds for the preparation of pharmaceutical compositions having an antiviral effect | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-01-06 | — | — | EP | claimed |
| US-20250041255-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES | YALE UNIVERSITY | 2025-02-06 | — | — | US | disclosed |
| US-10881656-B2 | HIF inhibitors and use thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2021-01-05 | — | — | US | disclosed |
| US-20170157111-A1 | HIF INHIBITORS AND USE THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2017-06-08 | — | — | US | disclosed |
| US-9604958-B2 | HIF inhibitors and use thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150023868-A1 | HIF INHIBITORS AND USE THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| US-20120070369-A1 | HIF INHIBITORS AND USE THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010068794-A2 | HIF INHIBITORS AND USE THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-0043141-B1 | PHARMACEUTICAL COMPOSITIONS HAVING ANTIVIRAL ACTIVITY FOR TOPICAL ADMINISTRATION AND THE USE OF 1-(SUBSTITUTED PHENYL)-5-(4-MORPHOLINYL)-1-PENTEN-3-ONE COMPOUNDS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING AN ANTIVIRAL EFFECT | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-09-12 | — | — | EP | disclosed |
| US-4400380-A | HERBES VIRUS; TOPICAL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-08-23 | — | — | US | disclosed |
| EP-0043141-A1 | Pharmaceutical compositions having antiviral activity for topical administration and the use of 1-(substituted phenyl)-5-(4-morpholinyl)-1-penten-3-one compounds for the preparation of pharmaceutical compositions having an antiviral effect | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881656-B2 | HIF inhibitors and use thereof | HIF1AN, HIF1A, EGLN3 | HSP90AA1 110/4885NPC1 1531/4885RAB9A 4101/4885 |
| US-20120070369-A1 | HIF INHIBITORS AND USE THEREOF | HIF1AN, HIF1A, EGLN3 | HSP90AA1 110/4885NPC1 1531/4885RAB9A 4101/4885 |
| US-20150023868-A1 | HIF INHIBITORS AND USE THEREOF | HIF1AN, HIF1A, EGLN3 | HSP90AA1 110/4885NPC1 1531/4885RAB9A 4101/4885 |
| US-20250041255-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES | HIF1AN, HIF1A, SSB | HSP90AA1 918/4885NPC1 4289/4885RAB9A 3489/4885 |
| US-20170157111-A1 | HIF INHIBITORS AND USE THEREOF | HIF1AN, HIF1A, EGLN3 | HSP90AA1 110/4885NPC1 1531/4885RAB9A 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.